Sarepta Therapeutics

Yahoo Finance • 3 days ago

Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

DENVER, May 27, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations acros... Full story

Yahoo Finance • 10 days ago

My Top 3 Biotech Stocks for May 2026

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large pharmaceutical companies are sitting on billio... Full story

Yahoo Finance • 10 days ago

Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock

Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the best gene therapy stocks to buy in 2026. Sarepta’s Q1 2026 report, released on May 6, showed that both earnings and revenue surpassed analysts’ expectations. Adjusted EPS of $3.16 smashe... Full story

Yahoo Finance • 23 days ago

Sarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.

Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown. Continue Reading... Full story

Yahoo Finance • 23 days ago

Sarepta (SRPT) Q1 2026 Earnings Transcript

Image source: The Motley Fool. Date Wednesday, May 6, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Douglas IngramPresident, Research and Development and Technical Operations — Louise Rodino-KlapacChief Commercial Of... Full story

Yahoo Finance • 26 days ago

Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?

Is PGEN a good stock to buy? We came across a bullish thesis on Precigen, Inc. on Valueinvestorsclub.com by coalone. In this article, we will summarize the bulls’ thesis on PGEN. Precigen, Inc.'s share was trading at $4.0200 as of April 28... Full story

Yahoo Finance • last month

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

CAMBRIDGE, Mass., April 22, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes... Full story

Yahoo Finance • last month

Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod

[Duchenne muscular dystrophy] Hailshadow Roche (RHHBY [https://seekingalpha.com/symbol/RHHBY]) announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics (SRPT [https:/... Full story

Yahoo Finance • 2 months ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 31, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensat... Full story

Yahoo Finance • 2 months ago

Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price... Full story

Yahoo Finance • 2 months ago

The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil

Quick Read Arm (ARM) surged 13% after unveiling its AGI CPU for agentic AI workloads, projecting $25B in total revenue and $9 per share in annual earnings within five years with $15B tied to the new chip, while Intel (INTC) rose 3% and AM... Full story

Yahoo Finance • 2 months ago

Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy Buyout

Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of muscular dystrophy. Continue Reading... Full story

Yahoo Finance • 2 months ago

2 Beaten-Down Stocks That Still Aren't Worth Buying

It's often wise to wait until a significant correction before investing in a stock. However, that strategy only works when the company can recover from whatever obstacle led to the sell-off. When that's not the case, investing in a beaten-... Full story

Yahoo Finance • 3 months ago

FDA vaccine chief to leave the agency again

[FDA Headquarters] For the second time in less than a year, Vinay Prasad, the head of the U.S. Food and Drug Administration’s vaccines unit, is leaving the agency, according to a statement from the FDA commissioner, Marty Makary. Prasad... Full story

Yahoo Finance • 3 months ago

Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics

Company Logo The oligonucleotides market offers opportunities in therapeutic applications, particularly for untreated diseases using ASOs, siRNA, and aptamers, with leaders like Alnylam driving innovation. Growth also spans diagnostics an... Full story

Yahoo Finance • 3 months ago

Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the best cheap biotech stocks to buy now. On February 27, Wells Fargo cut the price target on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $38 from $45 while maintaining an Overweight ratin... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

We came across a bullish thesis on Sarepta Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.'s share was trading at $18.88 as of February 20th. SRPT’s tr... Full story

Yahoo Finance • 3 months ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta Therapeutics, Inc.(NASDAQ:SRPT) shares are down during Thursday’s premarket session as the company reported its fourth-quarter and full-year 2025 financial results. Over the last year, the company’s stock has plunged from $106.86... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics Inc (SRPT) Q4 2025 Earnings Call Highlights: Strong Financial Position ...

This article first appeared on GuruFocus. Cash and Investments: $954 million at the end of 2025, with an increase of $89 million in the fourth quarter. Net Product Revenue for 2025: $1.86 billion, with $966 million from PMO franchise and... Full story